Improving small airways in uncontrolled asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether stepping up to either a higher dose of inhaled steroid/long-acting bronchodilator or a special fine-particle triple therapy (which includes an extra medication) can improve small-airway health in people whose asthma is still not well controlled on a medium-dose combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had asthma for at least 6 months.
- Your asthma is not well controlled (ACT score below 20 or ACQ-5 above 1.5) even though you have been taking a medium-dose inhaled steroid and long-acting bronchodilator combination for at least 12 weeks.
- A breathing test shows you have small-airway disease (FEF25-75% less than 60%).
- You can use a metered-dose inhaler correctly (with or without a spacer).
- You have not had a severe asthma attack requiring steroid pills or hospitalization in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to improve care for adults with asthma who have had a recent severe attack. It aims to see if better management can prevent future flare-ups.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study is testing an investigational medication for people with uncontrolled asthma. Participants must have moderate-to-severe asthma, be on appropriate maintenance therapy, and meet specific safety criteria.
This study tests an investigational drug to see if it can improve asthma control in people whose asthma is not well managed with current treatments. It may help reduce symptoms and improve lung function.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.